Scholar Rock Holding Corporation (SRRK) |
|
6.81 0.37 (5.75%)
|
09-26 15:49 |
|
Open: |
6.45 |
Pre. Close: |
6.44 |
|
High:
|
6.92 |
Low:
|
6.45 |
|
Volume:
|
402,632 |
Market Cap:
|
383(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 3:22:35 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 8.63 One year: 10.08 |
| Support: |
Support1: 6.48 Support2: 5.92 |
| Resistance: |
Resistance1: 7.38 Resistance2: 8.63 |
| Pivot: |
6.38 |
| Moving Average: |
MA(5): 6.58  MA(20): 6.32
MA(100): 7.05 MA(250): 8.1 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 42.2 %D(3): 37.8 |
| RSI: |
RSI(14): 57.1 |
| 52-week: |
High: 13 Low: 5.55 |
| Average Vol(K): |
3-Month: 315 (K) 10-Days: 464 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SRRK ] has closed below upper band by 7.3%. Bollinger Bands are 44.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.51 - 6.53 |
6.53 - 6.55 |
|
Low:
|
6.17 - 6.2 |
6.2 - 6.22 |
|
Close:
|
6.39 - 6.44 |
6.44 - 6.48 |
|
Company Description |
|
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Tue, 19 Sep 2023
Scholar Rock Announces Completion of Enrollment for the Phase 3 ... - Marketscreener.com
Thu, 07 Sep 2023
Fmr LLC Purchases 48252 Shares of Scholar Rock Holding Co ... - MarketBeat
Sun, 27 Aug 2023
Scholar Rock: Market Isn't Enthusiastic Despite Decent Clinical Data ... - Seeking Alpha
Mon, 21 Aug 2023
Scholar Rock Reports New Employee Inducement Grants under Nasdaq Listing Rule 5635(4) - Marketscreener.com
Wed, 09 Aug 2023
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress - Yahoo Finance
Thu, 13 Jul 2023
Wedbush Reiterates Scholar Rock Holding (SRRK) Outperform ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
56 (M) |
| Shares Float |
33 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
98.6 (%) |
|
Shares Short
|
5,350 (K) |
|
Shares Short P.Month
|
5,360 (K) |
Stock Financials |
|
EPS
|
-1.75 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.67 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.6 |
|
Return on Equity (ttm)
|
-60.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-1.6 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.83 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-131 (M) |
|
Levered Free Cash Flow
|
-67 (M) |
Stock Valuations |
|
PE Ratio
|
-3.95 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.86 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.95 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
